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Metastasisa b s t r a c t
The competitive endogenous RNAs (ceRNAs) are RNA molecules that affect each other’s expression
through competition for their shared microRNAs (miRNAs). In this study we explored whether
FOXO1 30UTR can function as a ceRNA in repressing epithelial-to-mesenchymal transition (EMT)
and metastasis of breast cancer cells via regulating miR-9 activity. We found that miR-9 binds to
both the FOXO1- and E-cadherin-30UTR, indicating that the FOXO1- and E-cadherin-30UTR can be
linked through miR-9. Follow-up analyses showed that there existed a competition of miR-9
between FOXO1 and E-cadherin-30UTR. Thus FOXO1 30UTR inhibits the metastases of breast cancer
cells via induction of E-cadherin expression. Our results suggest that FOXO1 30UTR may function
as a miRNA-inhibitor in modulating metastasis of breast cancer cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Breast cancer, one of the most common malignancies, is the
second leading cause of cancer death in women [1]. According to
previous researches, the metastasis of cancer cells is responsible
for majority of the deaths of breast cancer patients, and therefore
is regarded as the primary clinical challenge of breast cancer [2].
Two hypotheses have been postulated to explain the intricate nat-
ure of the metastatic process: (1) tumor stem cells, a population of
cells within the tumor mass, are able to proliferate, self-renew and
induce tumorigenesis, (2) epithelial-to-mesenchymal transition
(EMT), in which the epithelial cancer cells switch from a well-
differentiated phenotype to an invasive mesenchymal state in
pathological conditions [3].
MicroRNAs (miRNAs) are negative regulators of gene expression
by decreasing the stability of target RNAs or limiting their transla-
tion [4]. Most evidence indicated that miRNAs could be both posi-
tive and negative regulators of cancer metastasis by regulating the
process of EMT [5]. And recent study showed that miR-9 could
promote the progression of metastasis in breast cancer throughregulating E-cadherin expression directly and promoting EMT [6].
Previous studies showed that the expression of 30UTRs could act
as competing endogenous RNAs (ceRNAs) in regulating the func-
tion of endogenous miRNAs [7–11]. Conversely, protein-coding
transcripts, especially transcription factors like FOXO1, can bind
and regulate the function of miRNA [12], thus, these transcripts
regulate each other in the ceRNA networks [13–15].
FOXO1 belongs to the FOXO family of Forkhead transcription
factors, which have a conserved DNA binding domain termed the
Forkhead box (Fox) [16]. Increasing evidence suggests that FOXO1
is also involved in tumor metastases [17,18]. And restoring or
targeting FOXO1 to the cell nucleus in speciﬁc tissues may improve
the prognosis of breast cancer [19]. Some studies showed that
FOXO1 30UTR can be regulated by endogenous miRNAs, and the
regulation is coordinated by a group of miRNAs (miR-27a, miR-
96, and miR-182) in breast cancer cells [20]. However, it is unclear
whether FOXO1 30UTR can function as a ceRNA in regulating
mature miRNAs in breast cancer cells.
In this study, we conﬁrmed that FOXO1 30UTR was a direct
target of miR-9. Wound healing, Transwell Migration assay and
Adhesion Assay showed the suppression function of FOXO1 30UTR
on the metastases of breast cancer cells. Furthermore, we proved
the existence of a competition of miRNAs between FOXO1 30UTR
and E-cadherin 30UTR. To our knowledge, this is the ﬁrst study
demonstrating that the FOXO1 30UTR acts as E-cadherin ceRNA
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cer cells. Therefore, this study will provide novel perspectives into
the diagnosis and treatment of breast cancer.
2. Materials and methods
2.1. Cell culture
Human breast cancer cells MCF-7, MDA-MB-231, MDA-MB-453,
SKBR3 and normal breast epithelial cells MCF-10A were obtained
from the ATCC (Manassas, Virginia, USA). MCF-7, MDA-MB-231,
MDA-MB-453 and MCF-10A cells were cultured in the Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Gibco, Grand Island, NY) with
10% fetal bovine serum (FBS, Gibco, Grand Island, NY) at 37 C in
a humidiﬁed atmosphere with 5% CO2. SKBR3 was cultured in RPMI
1640 (Gibco, Grand Island, NY) media with 10% FBS at 37 C in a
humidiﬁed atmosphere with 5% CO2.
2.2. Plasmid construction
FOXO1 30UTR and E-cadherin 30UTR (CDH1 30UTR), which has
miR-9 binding sites were ampliﬁed by polymerase chain reaction








Then the PCR products were cloned into the pSilencer-4.1 vec-
tor (Ambion, Austin, USA), and the constructs were veriﬁed by
DNA sequencing. These recombinant plasmids were denoted
FOXO1 30UTR and CDH1 30UTR.
2.3. Transfection
Cells at the density of 5  105/well were harvested and seeded
in a 6-well plate. Four micrograms of DNA or 50 nM of RNA
(miR-9 mimics; miR-9 inhibitor; miRNA NC; FOXO1 siRNA; Dicer
siRNA; siRNA NC) (Biomics Biotechnology Inc., China) were trans-
fected into the cells by using the Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol.
2.4. Total RNA extraction and quantitative real time PCR (qRT-PCR)
Total RNA was extracted using the Trizol reagent (Invitrogen,
USA). Synthesis of ﬁrst strand cDNA was performed with M-MLV
(Promega, USA) following standard protocols. EzOmics SYBR qPCR,
miRNA qRT-PCR kit and miR-9 primer, which were purchased from
Biomics, were performed in a qRT-PCR detection system (ABI, USA).
The miR-9 expression level was normalized to U6 snRNA, then the
miR-9, FOXO1 and CDH1 relative expression level of each group
were calculated using the 2DDct method.
2.5. Wound healing assays
MCF-7 and MDA-MB-231 cells were transiently transfected
with FOXO1 30UTR, CDH1 30UTR and FOXO1 siRNA in a 6-well
plate. After 24 h, cells were allowed to grow to 90% – conﬂuent
in complete medium. Cell monolayers were wounded with a sterile
micropipette tip, and wounded monolayers were washed with
phosphate buffer solution (PBS) for several times to remove cell
debris, and then serum-free medium was added for further incu-
bating. The images of scratch were captured, and the distancesbetween two edges were scaled for three positions each time at
over three time points. Since MDA-MB-231 cells migrate faster
than MCF-7 cells, MDA-MB-231 and MCF-7 cells were measured
every 12 h and every 24 h respectively.
2.6. Transwell migration assay
Transwell migration assays were carried out by using 24-well
MILLIcell Hanging Cell Culture inserts 8 mm PET (MILLIPORE),
which were coated with Matrigel matrix gel (BD Biosciences). After
transfection, a total of 105 cells in serum-free medium were added
to the upper chamber and allowed to migrate toward the bottom
chamber. Twenty percentage FBS was used as a chemo-attractant
in the medium of the bottom chamber. MDA-MB-231 cells were
stopped at 10 h, and MCF-7 cells were stopped at 20 h. Cells on
the top surface of the membranes were removed with a cotton
swab, and cells on the underside were ﬁxed in methanol and
stained with 0.1% viola crystalline solution. Five random ﬁelds
from each of the triplicate migration assays were counted by using
phase contrast microscopy. Quantiﬁcation was done by measuring
with Microplate Reader (OD 570 nm) after being destained with
glacial acetic acid.
2.7. Adhesion assay
Microtiter wells were coated with matrix gel (BD Biosciences)
37 C, 4 h. Then the wells were blocked for 1 h with 1% BSA in
PBS. Transfected cells were trypsinized and suspended at a ﬁnal
concentration of 105 cells/well in serum-free medium. After 1 h
adhesion, non-adherent cells were washed away with PBS. The col-
orimetric MTT-assay was used to determine the number of adher-
ent cells.
2.8. Luciferase reporter assay
pMiR-Report Fluc vectors (Ambion) were used to introduce the
portion of the 30UTR of FOXO1 and CDH1 mRNA, the wild-type and
mutant binding sites for miR-9. These fragments were synthesized
by Sangon Biotech (Shanghai, China) and annealed as described.
The annealed oligonucleotides were ligated into pMiR-Report. In
order to test whether miR-9 were bounded directly to the 30UTR
of FOXO1 and E-cadherin, MCF-7 and MDA-MB-231 cells were
seeded in a 24-well plate (4  104 cells/well) and co-transfected
with pMiR-Report wild-type (WT) or mutant (MUT) sequences
(denoted as FW; FM; CW; CM), miR-9 mimics or cel-67 mimics
and pMiR-Report b-gal control plasmid (Ambion) using Lipofect-
amine 2000. After 48 h transfection, cells were collected and lucif-
erase activity was measured by a Glomax 96 luminometer
(Promega). The transfection efﬁciency was normalized to b-galac-
tosidase activity. In order to study whether FOXO1 30UTR or E-cad-
herin 30UTR could competingly bind endogenous miR-9, MCF-7
and MDA-MB-231 cells were seeded in 24-well tissue culture
plates and co-transfected with the luciferase reporter constructs
(FW; FM; CW; CM) and the 30UTR constructs (FOXO1 30UTR and
E-cadherin 30UTR) by using Lipofectamine 2000. Cells were col-
lected and measured by applying the method described after
transfection.
2.9. Western blot
After treatment, cells were washed twice with ice-cold PBS and
lysed in buffer RIPA (Beyotime, China), which contains 1 mM PMSF
(Beyotime), for 30 min (vortexed every 5 min) on ice, and then cen-
trifuged (400g) at 4 C for 10 min. The supernatant was separated
by 10% SDS–PAGE and transfered onto polyvinylidinediﬂuoride
membranes. The membranes were blocked in 5% BSA and
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washed and then incubated with horseradish peroxidase labeled
secondary antibodies for 2 h at room temperature. The FOXO1, E-
cadherin, vimentin, a-SMA, N-cadherin and Dicer antibody were
purchased from Epitomics and b-actin was purchased from Bio-
world. The speciﬁc protein bands were detected using the ECL
chemiluminescence detection kit (Beyotime, China), followed by
exposure to Kodak X-ray ﬁlms subjected to SDS–PAGE. The protein
expression level was normalized to b-actin.
2.10. Immunoﬂuorescent assay
Cells were grown on glass chamber slides, ﬁxed with 4% para-
formaldehyde in PBS for 30 min, permeabilized in 0.1% Triton X-
100 for 30 min and blocked with 3% BSA in PBS for 1 h at room
temperature. The cells were incubated with rabbit anti-human E-
cadherin and anti-vimentin antibody (Epitomics, Burlingame, CA)
overnight at 4 C. Then, the cells were incubated with FITC-conju-
gated secondary antibody (Bioworld, Atlanta, Georgia, USA) for 1 h
and observed with the Laser scanning confocal microscope. The
cells were washed with PBS after incubating each time.
2.11. Statistical analysis
The experimental results were shown as the mean ± S.E.M. for
three independent experiments. The differences between the
groups were analyzed using a two-sided Student’s t-test, and
P < 0.05 was considered signiﬁcant.Fig. 1. FOXO1 was coexpressed with E-cadherin and both were regulated by common mi
MCF-7, MDA-MB-453, SKBR3, MDA-MB-231 and MCF-10A cells measured by qRT-PCR a
MCF-10A) The normalized FOXO1 and E-cadherin expression for MCF-7 was set 1, ⁄P < 0
MDA-MB-231 and MCF-10A cells measured by real-time RT-PCR. The normalized miR-9
on FOXO1 and E-cadherin were predicted using Targetscan 6.1. (F, G) Luciferase reporte
galactosidase activity. ⁄P < 0.05, ⁄⁄P < 0.01 vs. NC group. (H) FOXO1 and E-cadherin protei
blot. (I) Quantitative data of densitometric analyses. The relative expression of FOXO1 a3. Results
3.1. FOXO1 was coexpressed with E-cadherin and both were regulated
by common miRNA in MCF-7 and MDA-MB-231 cells
We detected the expression of FOXO1 and E-cadherin in MCF-7,
MDA-MB-453, SKBR3, MDA-MB-231 and MCF-10A cells in mRNA
and protein levesl by using qRT-PCR andWestern blot respectively.
Results in Fig. 1A showed that the expression of FOXO1 in MCF-7, a
less metaststic tumor cell line, was 3.33-fold more than MDA-MB-
231, a highly metastatic tumor cell line. The expression level of E-
cadherin was similar to the expression level of FOXO1 in MCF-7
and MDA-MB-231 cells (Fig. 1A–C). We also looked at the expres-
sion of miR-9 in MCF-7, MDA-MB-453, SKBR3, MDA-MB-231 and
MCF-10A cells. The expression of miR-9 in MDA-MB-231 was
5.34-fold more than in MCF-7 cells (Fig. 1D). We found out that
miR-9 has putative target sites on both FOXO1 and E-cadherin by
using TargetScan 6.1 (www.targetscan.org) (Fig. 1E). To validate
whether FOXO1 and E-cadherin are bona ﬁde targets of miR-9,
human FOXO1 and E-cadherin 30UTR fragments containing wild-
type or mutant miR-9 binding site were introduced downstream
of the luciferase reporter gene. WhenmiR-9 mimics or cel-67 mim-
ics were cotransfected with the reporter plasmid, the relative lucif-
erase activity of the reporter containing wild-type FOXO1 and E-
cadherin 30-UTR were markedly suppressed, while the luciferase
activity of the reporter containing mutant 30-UTR was unaffected.
It indicated that FOXO1 and E-cadherin were direct targets of
miR-9 (Fig. 1F and G). Results in Fig. 1H and I showed that theRNA in MCF-7 and MDA-MB-231 cells. (A–C) Expression of FOXO1 and E-cadherin in
nd Western blot. (Fig. 1B, 1. MCF-7, 2. MDA-MB-453, 3. SKBR3, 4. MDA-MB-231, 5.
.05, ⁄⁄P < 0.01 vs. MCF-7. (D) Expression of miR-9 in MCF-7, MDA-MB-453, SKBR3,
expression for MCF-7 was set 1. ⁄P < 0.05, ⁄⁄P < 0.01 vs. MCF-7. (E) The miR-9 targets
r assay after transfection. Fluc activity in cells was measured and normalized to b-
n after transfecting with miR-9 mimics; inhibitor and NC were detected by Western
nd E-cadherin was normalized to b-actin. ⁄P < 0.05, ⁄⁄P < 0.01 vs. NC group.
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in MCF-7 and MDA-MB-231 cells after transfection with miR-9
mimics, whereas, miR-9 inhibitor increased the expression of
FOXO1 and E-cadherin in MDA-MB-231 cells and had little effect
on FOXO1 and E-cadherin expression in MCF-7 cells. This may be
due to a low level of endogenous miR-9 in MCF-7 cells. It revealed
that miR-9 could modulate FOXO1 and E-cadherin expression in a
post-transcriptional manner.
3.2. FOXO1 30UTR suppressed metastasis of MCF-7 and MDA-MB-231
cells
In order to examine the effect of FOXO1 30UTR on the metastasis
of MCF-7 and MDA-MB-231 cells, we overexpressed and knocked
down FOXO1 30UTR in MCF-7 and MDA-MB-231 cells. The efﬁ-
ciency of transfection was conﬁrmed by qRT-PCR and Western blot
(Fig. 2F and L). The motility of MCF-7 and MDA-MB-231cells was
examined by wound healing assay. MCF-7 and MDA-MB-231 cells
were transfected with FOXO1 30UTR and vertical migration was
assessed. A signiﬁcant difference in cell migration was observed
between FOXO1 30UTR and control vector transfected breast cancer
cells. Cell migration was decreased in FOXO1 30UTR-transfected
cells compared with controls (Fig. 2A and B). To ﬁnd out whether
there is a correlation existed between FOXO1 30UTR and tumor
invasiveness, MCF-7 and MDA-MB-231 cells were transfected with
either FOXO1 30UTR or control vectors. As shown in Fig. 2C, we
found that invasive activity of FOXO1 30UTR-transfected MCF-7Fig. 2. FOXO1 30UTR suppressed metastasis of MCF-7 and MDA-MB-231 cells. (F, L) The e
NC group. (A, B) Effects of FOXO1 30UTR on MCF-7 and MDA-MB-231 cells migration in
MCF-7 and MDA-MB-231 cells (C) Photographs of the cell invasion through the polycarb
Effects of FOXO1 30UTR on adhesion to matrix gel of MCF-7 and MDA-MB-231 cells. ⁄⁄P
MDA-MB-231 cells. (I, J) Effects of FOXO1 siRNA on cell invasion in MCF-7 and MDA-MB-
stained with crystal violet (200). (J) OD570 of stain crystal violet. (K) Effects of FOXO1
group.and MDA-MB-231 cells was markedly attenuated compared to vec-
tor control (Fig. 2C and D). We also examined the inﬂuence of
FOXO1 30UTR on the adhesion activities of breast cancer MCF-7
and MDA-MB-231 cells to the substrates precoated with matrix
gel, which is a basement member component. After transfected
with FOXO1 30UTR, the adhesion activity was decreased in MCF-7
and MDA-MB-231 cells (Fig. 2E). Following FOXO1 30UTR knock
down, the cell migration adhesion and invasion phenotypes were
signiﬁcantly increased compared to the treatment of negative con-
trol (NC) in MCF-7 and MDA-MB-231 cells (Fig. 2G–K). In sum-
mary, these results showed that FOXO1 30UTR expression can
inhibit metastasis of MCF-7 and MDA-MB-231 cells.
3.3. FOXO1 30UTR promoted E-cadherin expression, thus inhibiting
EMT in MCF-7 and MDA-MB-231 cells
Our experiments showed that the FOXO1 30UTR transfected
cells expressed higher levels of E-cadherin compared to vector con-
trol (Fig. 3A). E-cadherin expression in MCF-7 and MDA-MB-231
cells was increased by 2.30 and 2.22-fold separately (Fig. 3B). How-
ever, The expression of E-cadherin in FOXO1 siRNA transfected
MCF-7 and MDA-MB-231 cells was reduced by 2.52 and 2.43-fold
separately compared to NC (Fig. 3C and D). The currently and com-
monly used biomarkers of mesenchymal cells such as N-cadherin,
vimentin and a-SMA were used to identify the EMT phenomenon.
Protein levels of N-cadherin; vimentin and a-SMA were reduced in
FOXO1 30UTR transfeted cells (Fig. 3E and F). In contrast, knockfﬁciency of transfection was conﬁrmed by qRT-PCR and Western blot. ⁄⁄P < 0.01 vs.
vitro. ⁄⁄P < 0.01 vs. Control group. (C, D) Effects of FOXO1 30UTR on cell invasion in
onate membrane stain by crystal violet (200). (D) OD570 of stain crystal violet. (E)
< 0.01 vs. NC group. (G, H) Effects of FOXO1 siRNA on cell migration in MCF-7 and
231 cells. (I) Photographs of the cell invasion through the polycarbonate membrane
siRNA on adhesion to matrix gel of MCF-7 and MDA-MB-231 cells. ⁄⁄P < 0.01 vs NC
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signiﬁcant increase in the expression of mesenchymal markers
(Fig. 3G and H). Meanwhile, immunoﬂuorescence assay showed
that the expression of E-cadherin was up-regulated in MCF-7 and
MDA-MB-231 cells when treated with FOXO1 30UTR (Fig. 3I).
Whereas, vimentin expression was down-regulated in FOXO1
30UTR transfected breast cancer cells compared with control
(Fig. 3J). The morphology of cells treated with FOXO1 30UTR chan-
ged from long shuttleshape to spherical, especially in MDA-MB-
231 cells, which have higher metastasis potential.
3.4. Regulation of E-cadherin by FOXO1 30UTR was miRNA dependent
in MCF-7 and MDA-MB-231 cells
To decipher the nature of the relationship between FOXO1
30UTR and E-cadherin 30UTR, we expressed FOXO1 30UTR luciferase
reporter (FW) or E-cadherin 30UTR luciferase reporter (CW) in
MCF-7 and MDA-MB-231 cells, the results showed that overex-
pression of FOXO1 30UTR signiﬁcantly increased E-cadherin 30UTR
luciferase reporter (CW) activity, but the activity of FOXO1 30UTR
luciferase reporter (FW) remained unaltered in E-cadherin 30UTR
overexpressing cells (Fig. 4A). However, FOXO1 30UTR mediated
increase of E-cadherin activity was lost when Dicer was knocked
down. E-cadherin expression was not altered when we cotrans-
fected FOXO1 30UTR with Dicer siRNA (Fig. 4B and D). When FOXO1
siRNA was co-expressed with Dicer siRNA, the expression of E-cad-
herin stayed the same in MCF-7 and MDA-MB-231 cells (Fig. 4C
and E). The efﬁciency of transfection was conﬁrmed by western
blot (Fig. 4F and G).Fig. 3. FOXO1 30UTR promoted E-cadherin expression, thus inhibiting EMT in MCF-7 and
cadherin protein expression after transfection with FOXO1 30UTR, The relative express
detected in FOXO1 30UTR transfected cells. ⁄⁄P < 0.01 vs. NC group. (C, D) After FOXO1 30
relative expression of E-cadherin was normalized to b-actin. ⁄⁄P < 0.01 vs. NC group. (E–
Expression of vimentin; N-cadherin and a-SMA by western blot with overexpression or k
analyses. ⁄⁄P < 0.01 vs. NC group. (I, J) Immunoﬂuorescence analysis of E-cadherin and vi
were immunostained with anti-E-cadherin and antin-vimentin, blue, nuclei were staine4. Discussion
In this study, we provided evidence that FOXO1 30UTR can func-
tion as a ceRNA in competitively binding with miR-9, and therefore
relieve the suppression of E-cadherin from miR-9 and up-regulate
the expression of E-cadherin in breast cancer cells. E-cadherin is a
cell–cell adhesion molecule that forms complexes with catenin
family members and regulates association with the cytoskeleton
and catenin/WNT signaling pathways. It is a critical molecule in
the EMT process. The metastases are correlated with the low level
of E-cadherin occurring in the EMT [21]. A study suggested that the
disruption of E-cadherin junctions and consequent gain of cell
motility contribute to the process known as EMT in breast cancer
cells. Conversely, overexpression of E-cadherin suppresses tumor
invasion [22–24]. Thus, our results suggested that FOXO1 30UTR
suppressed the metastases of MCF-7 and MDA-MB-231 cells by
promoting the expression of E-cadherin and repressing EMT.
The prevalent view is that protein-coding gene must be trans-
lated into a protein to exert function. FOXO1-coded protein, which
acts as a key tumor suppressor, has been extensively studied [25–
27]. Previous studies showed that FOXO1 participates in many bio-
logical events [28–32]. Recent studies indicated that miRNAs mod-
ulate FOXO1 expression through binding to FOXO1 30UTR, which
has miRNA response elements (MRES) in breast cancer cells [20].
However, there have been few reports about the regulation of
FOXO1 30UTR on miRNAs. Here we used ceRNA hypothsis to
explain the regulatory function of FOXO1 30UTR. Competing endog-
enous RNA (ceRNA) hypothesis, which had been proved in recent
studies, is a unifying hypothesis about how messenger RNAs,MDA-MB-231 cells. (A, B) Western blot analysis of MCF-7 and MDA-MB-231 for E-
ion of E-cadherin was normalized to b-actin. Increased E-cadherin expression was
UTR being koncked down, E-cadherin expression was detected by western blot. The
H) FOXO1 30UTR affected vimentin; N-cadherin and a-SMA at protein level. (E, G)
nockdown of FOXO1 30UTR. (F, H) Representative quantitative data of densitometric
mentin expression after transfecting FOXO1 30UTR. Green, E-cadherin and vimentin
d with DAPI.
Fig. 4. Regulation of E-cadherin by FOXO1 30UTR is miRNA dependent in MCF-7 and MDA-MB-231 cells. (A) FOXO1 30UTR and E-cadherin 30UTR luciferase activity in MCF-7
and MDA-MB-231cells transfected with the 30UTR of negative control (pSilencer 4.1), FOXO1 or E-cadherin 30UTR. ⁄⁄P < 0.01 vs. NC group. (B) When added FOXO1 30UTR plus
Dicer siRNA, E-cadherin expression was not altered. (C) When FOXO1 siRNA was co-expressed with Dicer siRNA, the expression of E-cadherin stayed the same in MCF-7 and
MDA-MB-231 cells. (D, E) Representative quantitative data of densitometric analyses. ⁄⁄P < 0.01 vs. NC group. (F, G) The efﬁciency of transfection was conﬁrmed by Western
blot. ⁄⁄P < 0.01 vs. NC group.
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regulate each other’s expression by miRNA response elements
(MREs) to compete for the binding of miRNAs [21–25]. Throuth a
series of experiments, our research conﬁrmed that FOXO1 30UTR
can function as a ceRNA of E-cadherin and act in trans to modulate
E-cadherin levels by competitively binding to miR-9 in breast can-
cer cells. However, other study showed that FOXO1 directly regu-
lated matrix metalloprotease 1 transcription, and Cdc25A
inﬂuenced matrix metalloprotease 1 through regulating nuclear
localization and stability of FOXO1 [33]. This study found that
FOXO1 has a role of pro-metastasis in breast cancer cells. These
controversial ﬁndings revealed that non-coding function of mRNA
might be adverse to the coding function, thus creating functional
complexity and diversiﬁcation in both physiological and patholog-
ical conditions. Accordingly it is important to study non-coding
function of mRNA.
Our results proved that expressing non-coding transcript may
have a dramatic function of regulating gene expression. Exogenous
expression of the 30UTR construct altered the expression of some
proteins that are functionally associated with the 30UTR. For our
study, we constructed FOXO1 30UTR that only contained miR-9
binding site. However, computational analysis of the FOXO1 30UTR
has shown that miR-27a, miR-96 and miR-182 could interact with
FOXO1 30UTR. Recent studies have reported that miR-27a, miR-96
and miR-182 have oncogenic activities in breast cancer [34–36].
Long sequence of the 30UTR that contains miR-27a, miR-96 and
miR-182 binding sites can be constructed for further research. Its
capacity of exerting complex biological activities may be observed.
We predict that the effectiveness of 30UTR will depend on the num-
ber of miRNAs that it can ‘‘sponge’’ which arrest miRNA activity.
Further experiments are needed to prove our hypothesis. Althougha ceRNA networks can be built around a single miRNA, more atten-
tion should be paid on the most robust ceRNA network that con-
tains transcripts, which share multiple MREs targeted by
multiple miRNAs. CeRNA networks may depend on the identity,
concentration, and subcellular distribution of the miRNA species.
Our results showed that the expression of the 30UTR could pro-
duce a similar functional role as the miRNA inhibitor. However,
30UTR has a more potent effect compared to miRNA inbibitor in
some aspects. Firstly, one 30UTR has the capacity to modulate mul-
tiple miRNAs, while one miRNA inhibitor can only affect one miR-
NA. Secondly, a long fragment of 30UTR seems more stable than the
miRNA inhibitor, which may be readily degraded. Therefore, the
expression of a 30UTR may have a greater advantage in modulating
cell activities compared to miR-9 inhibitor, providing a potential
use for 30UTR transcript in gene therapy.
Our results showed that FOXO1 30UTR overexpression signiﬁ-
cantly increased the activity of E-cadherin 30UTR luciferase repor-
ter, while the activity of FOXO1 30UTR luciferase reporter was not
dramatically altered in E-cadherin 30UTR overexpressing cells. This
result suggested the superiority of FOXO1 30UTR in the competition
of miRNA, in comparison to E-cadherin 30UTR. Our results indi-
cated that not all of the MREs on ceRNAs are equivalent. The ceRNA
effect is known to be determined by not only the sequence depen-
dent binding afﬁnity, but also the relative concentration of the ceR-
NAs. Therefore, the MRE’s nucleotide composition of ceRNAs is
critical for the overall ceRNA function when its concentration stays
unchanged. Some studies tried to assess the probability of interac-
tion between two moleculars via mathematical/computational
analysis [37]. However, no further evidence has been given to sup-
port these theories. Therefore, it is necessary to develop more prac-
tical methods to solve these questions. Interestingly, Our results
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overexpressing MCF-7 cells than that in MDA-MB-231 cells. Here,
FOXO1 30UTR acted as a ceRNA of E-cadherin. The effectiveness
of a ceRNA depends on not only its expression, but also the ceRNA’s
accessibility to miRNA molecules, which is inﬂuenced by its sub-
cellular localization and its interaction with RNA-binding proteins.
Thus, we suppose that the afﬁnity between FOXO1 30UTR and miR-
9 in MCF-7 cells might be stronger than that in MDA-MB-231 cells,
because different subtypes of cells might have various internal
microenvironment. We suggest that this stronger afﬁnity might
explain that E-cadherin expression was higher in FOXO1 30UTR
overexpressing MCF-7 cells. However, this hypothesis needs fur-
ther veriﬁcation. CeRNA networks are very complicated gene regu-
latory networks and might be inﬂuenced by multiple factors. Only
when we solve all these problems and do more complete study can
we fully utilize the ceRNA networks to defeat disease.
All together, our study suggested that FOXO1 30UTR may be a
promising miRNA-inhibitor, which can be applied in the gene ther-
apy for breast cancer. Moreover, ceRNA networks might provide
new perspectives into the diagnosis and treatment of disease.
Although the exploration and studies in this ﬁeld are still in their
infancy, we believe that ceRNA network will be thoroughly under-
stood and present opportunities for new therapies with the pro-
gress of experimental tools.
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